Parkinson's genetics: Molecular insights for the new millennium

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 503-514

  Skipper, Lisa ^a   Farrer, Matt ^a  

^a MAYO CLINIC   (United States)

Author keywords

Familial parkinsonism; Molecular genetics

Indexed keywords

ALPHA SYNUCLEIN; GENE PRODUCT; PARKIN; PROTEIN UCH L1; TAU PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; LIGASE; NERVE PROTEIN; SYNUCLEIN; UBIQUITIN PROTEIN LIGASE;

CONFERENCE PAPER; FAMILIAL DISEASE; FAMILY HISTORY; GENE LOCUS; GENE MAPPING; GENOTYPE; HEREDITY; HUMAN; INHERITANCE; LINKAGE ANALYSIS; MICROTUBULE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SYNTHESIS; ANIMAL; GENETICS; MOLECULAR BIOLOGY; REVIEW;

ANIMALS; HUMANS; LIGASES; MOLECULAR BIOLOGY; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SYNUCLEINS; TAU PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 0036777846     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00038-4     Document Type: Conference Paper

References (136)

1. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, de Michele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe: French Parkinson's disease genetics study group and the European consortium on genetic susceptibility in Parkinson's disease. Hum Mol Genet 1999a;8:567-74.
2. Abbas N, Lücking CB, Ricard S, Dürr A, Bonifati V, DeMichele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 1999;8:567-74.
3. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-52.
4. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-12.
5. Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 1999;843:53-61.
6. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8:711-5.
7. Barbieri S, Hofele K, Wiederhold KH, Probst A, Mistl C, Danner S, et al. Mouse models of alpha-synucleinopathy and Lewy pathology: alpha-synuclein expression in transgenic mice. Adv Exp Med Biol 2001;487:147-67.
8. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552-5.
9. Blakely RD. Neurobiology: dopamine's reversal of fortune. Science 2001;293:2407-9.
10. 18F-DOPA and positron emission tomography. Neurology 1992;42:1894-900.
11. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet 1983;2:1457-9.
12. Chen L, Shinde U, Ortolan TG, Madura K. Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep 2001;2:933-8.
13. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 2001;10:3101-9.
14. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J. Parkin ubiquitinates the alpha-synuclein interacting protein, synphilin 1: implications for Lewy body formation in Parkinson disease. Nat Med 2001;7:1144-50.
15. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999;58:120-9.
16. Conrad C, Amano N, Andreadis A, Xia Y, Namekataf K, Oyama F, et al, Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: implication for progressive supranuclear palsy. Neurosci Lett 1998;250:135-7.
17. Conway KA, Rochet JC, Bieganski RM, Lansbury Jr, PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294:1346-9.
18. de Silva R, Farrer M. Tau neurotoxicity without the lesions: a fly challenges a tangled web. Trends Neurosci. 2002;25:327-9.
19. DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, et al. Genome-wide scan for Parkinson's disease: the gene PD study. Neurology 2001;57:1124-6.
20. Dickson DW. Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol 2001;14:423-32.
21. Dickson D, Farrer M, Lincoln S, Mason RP, Zimmerman Jr, TR, Golbe LI. Pathology of PD in monozygotic twins with a 20-year discordance interval. Neurology 2001;56:981-2.
22. Elbaz A, Grigoletto F, Baldereschi M, Breteler MM, Manubens-Bertran JM, Lopez-Pousa S, et al. Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EUROPARKINSON study group. Neurology 1999;52:1876-82.
23. Farrer M, Wavrant-De Vrieze F, Crook R, Boles L, Perez-Tur J, Hardy J, et al. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann Neurol 1998;43:394-7.
24. Farrer M, Gwinn-Hardy K, Hutton M, Hardy J. The genetics of disorders with synuclein pathology and parkinsonism. Hum Mol Genet 1999a;8:1901-5.
25. Farrer M, Gwinn-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 1999b;8:81-5.
26. Farrer M, Destee T, Becquet E, Wavrant-De Vrieze F, Mouroux V, Richard F, et al. Linkage exclusion in French families with probable Parkinson's disease. Mov Disord 2000;15:1075-83.
27. Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001a;50:293-300.
28. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001b;10:1847-51.
29. Farrer M, Skipper L, Berg M, Bisceglio G, Hanson M, Hardy J, et al. The Tau H1 Haplotype is associated with Parkinson's disease in the Norwegian population. Neurosci Lett 2002;322:83-6.
30. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404:394-8.
31. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51:296-301.
32. Gasser T, MullerMyhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-5.
33. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
34. Golbe LI, Lazzarini AM, Spychala JR, Johnson WG, Stenroos ES, Mark MH, et al. The tau A0 allele in Parkinson's disease. Mov Disord 2001;16:442-7.
35. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998;50:1346-50.
36. Gwinn-Hardy K, Chen JY, Liu HC, Liu TY, Boss M, Seltzer W, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000;55:800-5.
37. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, Boss M, Nicholl D, Adam A, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol 2001;58:296-9.
38. Hardy J. Genetic dissection of primary neurodegenerative diseases. Biochem Soc Symp 2001:51-7.
39. Harhangi BS, Farrer MJ, Lincoln S, Bonifati V, Meco G, de Michele G, et al. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci Lett 1999;270:1-4.
40. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001;32:213-23.
41. Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, et al. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive-juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol 1998a;44:935-41.
42. Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, et al. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol 1998;44:935-41.
43. Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, et al. Point mutations (Thr240Arg and Gln311Stop, correction of Thr240Arg and Ala311Stop) in the parkin gene [published erratum appears in Biochem Biophys Res Commun 20 Oct 1998;251(2):666]. Biochem Biophys Res Commun 1998;251:666.
44. Hayashida K, Oyanagi S, Mizutani Y, Yokochi M. An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism. Acta Neuropathol (Berl) 1993;85:445-8.
45. Hicks A, Petursson H, Jonsson T, Stefansson HJH, Sainz J, Frigge ML, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease successfully mapped. Am J Hum Genet 2001;69:200.
46. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psych 1992;55:181-4.
47. Hutton M. Molecular genetics of chromosome 17 tauopathies. Ann New York Acad Sci 2000;920:63-73.
48. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
49. Huynh DP, Scoles DR, Ho TH, Del Bigio MR, Pulst SM. Parkin is associated with actin filaments in neuronal and non-neural cells. Ann Neurol 2000;48:737-44.
50. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001;105:891-902.
51. Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal recessive type juvenile parkinsonism. Neurology 1996;47:160-6.
52. Ishikawa A, Takahashi H. Clinical and neuropathological aspects of autosomal recessive-juvenile parkinsonism. J Neurol 1998;245:4-9.
53. Jana NR, Tanaka M, Wang G, Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 2000;9:2009-18.
54. Jenco JM, Rawlingson A, Daniels B, Morris AJ. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry 1998;37:4901-9.
55. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:S161-70.
56. Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson's disease: a reappraisal. Mov Disord 1990;5:187-94.
57. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.
58. Kleppe R, Toska K, Haavik J. Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association. J Neurochem 2001;77:1097-107.
59. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000;10:524-30.
60. Kramer PL, Mineta M, Klein C, Schilling K, de Leon D, Farlow MR, et al. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Ann Neurol 1999;46:176-82.
61. Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci USA 2000;97:1589-94.
62. Kruger R, Kuhn W, Muller T, Wuitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
63. Kruger R, Vieira-Saecker AM, Kuhn W, Berg D, Muller T, Kuhnl N, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/apolipoprotein E genotype. Ann Neurol 1999;45:611-7.
64. Kuopio A, Marttila RJ, Helenius H, Rinne UK. Familial occurrence of Parkinson's disease in a community-based case-control study. Parkinsonism Relat Disord 2001;7:297-303.
65. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. Mov Disord 1999;14:928-39.
66. 18F]6-fluorodopa PET. J Neurol 2000;247:II110-3.
67. Langston JW. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol 1998;44:S45-52.
68. Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S. Genomic organization and expression of the human β-synuclein gene (SNCB). Genomics 1998;54:173-5.
69. Leng Y, Chase TN, Bennett MC. Muscarinic receptor stimulation induces translocation of an α-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem 2001;276:28212-8.
70. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-2.
71. Lincoln S, Vaughan J, Wood N, Baker M, Adamson J, Gwinn-Hardy K, et al. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 1999;10:427-9.
72. Litvan I, Lees AJ. Progressive supranuclear palsy. Adv Neurol 1999;80:341-5.
73. Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 1990;161:153-60.
74. Lucking CB, Abbas N, Durr A, Bonifati V, Bonnet AM, de Broucker T, et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive-juvenile parkinsonism: the European consortium on genetic susceptibility in Parkinson's disease and the french Parkinson's disease genetics study group [letters]. Lancet 1998;352:1355-6.
75. Lucking CB, Durr A, Bonifati V, Vaughan J, de Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene: French Parkinson's disease genetics study group. N Engl J Med 2000;342:1560-7.
76. Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, et al. Epidemiologic study of 203 sibling pairs with Parkinson's disease: the gene PD study. Neurology 2002;58:79-84.
77. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999;53:1858-60.
78. Maraganore DM, Hernandez DG, Singleton AB, Farrer MJ, McDonnell SK, Hutton ML, et al. Case-control study of the extended tau gene haplotype in Parkinson's disease. Ann Neurol 2001;50:658-61.
79. Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996;47:155-60.
80. Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, et al. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 1998;50:279-81.
81. Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 2001;286:2245-50.
82. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 2001;98:12245-50,
83. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
84. Menza M. The personality associated with Parkinson's disease. Curr Psych Rep 2000;2:421-6.
85. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002;51:133-6.
86. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-2.
87. Ninkina NN, Alimova-Kost MV, Paterson JW, Delaney L, Cohen BB, Imreh S, et al. Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet 1998;7:1417-24.
88. Nisipeanu P, Inzelberg R, Blumen SC, Carasso RL, Hattori N, Matsumine H, et al. Autosomal recessive-juvenile parkinsonism in a Jewish Yemenite kindred: mutation of parkin gene. Neurology 1999;53:1602-4.
89. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Palacino J, et al. α-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999;19:5782-91.
90. Payami H, Zareparsi S, Genetic epidemiology of Parkinson's disease. J Geriatr Psych Neurol 1998;11:98-106.
91. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994;36:659-61.
92. Perez RG, Waymire JC, Lin E, Liu JJ, Gou F, Zigmond MJ. A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002;22:3090-9.
93. Periquet M, Lucking C, Vaughan J, Bonifati V, Durr A, de Michele G, et al. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. Am J Hum Genet 2001;68:617-26.
94. 18F-DOPA positron emission tomography. Adv Neurol 1999;80:227-31.
95. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197-9.
96. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
97. Pothos EN. Regulation of dopamine quantal size in midbrain and hippocampal neurons. Behav Brain Res 2002;130:203-7.
98. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001;86:122-7.
99. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999;23:47-51.
100. Saito Y, Kawai M, Inoue K, Sasaki R, Arai H, Nanba E, et al. Widespread expression of α-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 2000;177:48-59.
101. Satoh J, Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J Neurol Sci 2001;189:113-7.
102. Schenk D, Seubert P, Ciccarelli RB. Immunotherapy with β-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol 2001;20:679-81.
103. Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001;286:2239-44.
104. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, et al. Immunohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive-juvenile parkinsonism patients. Ann Neurol 1999;45:668-72.
105. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5.
106. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-9.
107. Simon DK, Standaert DG. Neuroprotective therapies. Med Clin North Am 1999;83(8):509-23.
108. Simon DK, Pulst SM, Sutton JP, Browne SE, Beal MF, Johns DR. Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology 1999;53:1787-93.
109. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997;388:839-40.
110. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002;156:1051-63.
111. Surguchov A, Surgucheva I, Solessio E, Baehr W. Synoretin: a new protein belonging to the synuclein family. Mol Cell Neurosci 1999;13:95-103.
112. Sveinbjornsdottir S, Hicks AA, Jonsson T, Petursson H, Gugmundsson G, Frigge ML, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000;343:1765-70.
113. Swerdlow RH, Parks JK, Davis 2nd, JN, Cassarino DS, Trimmer PA, Currie LJ. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 1998;44:873-81.
114. Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology 2000;54:1195-8.
115. Tanner CM, Aston DA. Epidemiology of Parkinson's disease and akinetic syndromes [in process citation]. Curr Opin Neurol 2000;13:427-30.
116. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.
117. Touchman JW, Dehejia A, Chiba-Falek O, Cabin DE, Schwartz JR, Orrison BM, et al. Human and mouse α-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res 2001;11:78-86.
118. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-6.
119. Uitti RJ, Shinotoh H, Hayward M, Schulzer M, Mak E, Calne DB. "Familial Parkinson's disease": a case-control study of families. Can J Neurol Sci 1997;24:127-32.
120. Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001;68:895-900.
121. Valente EM, Brancati F, Ferraris A, Graham EA, Davis MB, Breteler MM, et al. Park6-linked parkinsonism occurs in several European families. Ann Neurol 2002;51:14-8.
122. van de Warrenburg BP, Lammens M, Lucking CB, Denefle P, Wesseling P, Booij J, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-7.
123. van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ. Park7: a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001;69:629-34.
124. Vaughan JR, Farrer MJ, Wszolek ZK, Gasser T, Durr A, Agid Y, et al. Sequencing of the α-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations: the European consortium on genetic susceptibility in Parkinson's disease (GSPD). Hum Mol Genet 1998;7:751-3.
125. Vieregge P, Friedrich HJ, Rohl A, Ulm G, Heberlein I. Multifactorial etiology of idiopathic Parkinson disease. a case-control study. Nervenarzt 1994;65:390-5.
126. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001;12:1393-407.
127. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-24.
128. Wenning GK, Seppi K, Scherfler C, Stefanova N, Puschban Z. Multiple system atrophy. Semin Neurol 2001;21:33-40.
129. West A, Periquet M, Lincoln S, Lücking CB, Nicholl D, Bonifati V, et al. The complex relationship between parkin mutations and Parkinson's disease. Hum Mol Genet 2002.
130. Wilhelmsen KC, Weeks DE, Nygaard TG, Moskowitz CB, Rosales RL, dela Paz DC, et al. Genetic mapping of "Lubag" (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol 1991;29:124-31.
131. Wintermeyer P, Kruger R, Kuhn W, Muller T, Woitalla D, Berg D, et al. Mutation analysis and association studies of the UCH-L1 gene in German Parkinson's disease patients. Neuroreport 2000;11:2079-82.
132. Yamamura Y, Arihiro K, Kohriyama T, Nakamura S. Early-onset parkinsonism with diurnal fluctuation: clinical and pathological studies. Rinsho Shinkeigaku 1993;33:491-6.
133. Yamao F. Ubiquitin system: selectivity and timing of protein destruction. J Biochem [Tokyo] 1999;125:223-9.
134. Yokochi M, Narabayashi H, Iizuka R, Nagatsu T. Juvenile parkinsonism: some clinical, pharmacological, and neuropathological aspects. Adv Neurol 1984;40:407-13.
135. Zhang J, Hattori N, Leroy E, Morris HR, Kubo S, Kobayashi T, et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat Disord 2000a;6:195-7.
136. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCre-1. Proc Natl Acad Sci USA 2000;97:13354-9,